MeiraGTx Holdings (MeiraGTx Holdings) FCF Margin % : -861.62% (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is MeiraGTx Holdings FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. MeiraGTx Holdings's Free Cash Flow for the three months ended in Dec. 2023 was $-17.58 Mil. MeiraGTx Holdings's Revenue for the three months ended in Dec. 2023 was $2.04 Mil. Therefore, MeiraGTx Holdings's FCF Margin % for the quarter that ended in Dec. 2023 was -861.62%.

As of today, MeiraGTx Holdings's current FCF Yield % is -39.12%.

The historical rank and industry rank for MeiraGTx Holdings's FCF Margin % or its related term are showing as below:

MGTX' s FCF Margin % Range Over the Past 10 Years
Min: -895.62 Med: -648.89 Max: 83.25
Current: -895.62

During the past 8 years, the highest FCF Margin % of MeiraGTx Holdings was 83.25%. The lowest was -895.62%. And the median was -648.89%.

MGTX's FCF Margin % is ranked worse than
74.69% of 1035 companies
in the Biotechnology industry
Industry Median: -149.8 vs MGTX: -895.62

MeiraGTx Holdings FCF Margin % Historical Data

The historical data trend for MeiraGTx Holdings's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MeiraGTx Holdings FCF Margin % Chart

MeiraGTx Holdings Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

83.25

-648.89

-174.39

-741.59

-895.62

MeiraGTx Holdings Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															468.21	-1,379.63	-960.08	-548.27	-861.62

Competitive Comparison of MeiraGTx Holdings's FCF Margin %

For the Biotechnology subindustry, MeiraGTx Holdings's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MeiraGTx Holdings's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MeiraGTx Holdings's FCF Margin % distribution charts can be found below:

* The bar in red indicates where MeiraGTx Holdings's FCF Margin % falls into.

MeiraGTx Holdings FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

MeiraGTx Holdings's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-125.539	/	14.017
	=	-895.62 %

MeiraGTx Holdings's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-17.577	/	2.04
	=	-861.62 %

MeiraGTx Holdings FCF Margin % Related Terms

Thank you for viewing the detailed overview of MeiraGTx Holdings's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

MeiraGTx Holdings (MeiraGTx Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MeiraGTx Holdings PLC (NAS:MGTX) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

328:Germany

Address

450 East 29th Street, 14th Floor, New York, NY, USA, 10016

Website

https://www.meiragtx.com

MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.

Executives

Perceptive Life Sciences Master Fund Ltd	director, 10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Johnson & Johnson Innovation - Jjdc, Inc.	10 percent owner	410 GEORGE STREET, NEW BRUNSWICK NJ 08901
Johnson & Johnson	10 percent owner	ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ 08933
Robert K Zeldin	officer: Chief Medical Officer	C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Robert J Wollin	officer: General Counsel and Secretary	450 EAST 29TH STREET, 14TH FLOOR, NEW YORK NY 10016
Debra Yu	director	C/O PERCEPTIVE ADVISORS, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Alexandria Forbes	director, officer: President & CEO	C/O KADMON HOLDINGS, LLC, 450 E. 29TH STREET, NEW YORK NY 10016
Richard Giroux	officer: Chief Operating Officer	C/O MEIRAGTX - US, 430 EAST 29TH STREET, 10TH FLOOR, NEW YORK NY 10016
Stuart Naylor	director, officer: Chief Dev. Officer	C/O MEIRAGTX - US, 430 EAST 29TH STREET, 10TH FLOOR, NEW YORK NY 10016
Joel S Marcus	director	C/O ALEXANDRIA REAL ESTATE EQUITIES, INC, 26 NORTH EUCLID AVENUE, PASADENA CA 91101
Thomas E Shenk	director	C/O KADMON HOLDINGS, LLC, 450 E. 29TH STREET, NEW YORK NY 10016
Nicole Seligman	director	C/O VIACOM INC., 1515 BROADWAY, NEW YORK NY 10036
Perceptive Advisors Llc	director, 10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Ellen Hukkelhoven	director	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003